AstraZeneca’s Imfinzi shows promise in gastric cancer trial

AstraZeneca PLC (LSE/STO/NASDAQ: LON:AZN), a pharmaceutical giant with a market capitalization of $239.66 billion and impressive revenue growth of 18% over the last twelve months, has reported positive outcomes from its MATTERHORN Phase III trial, which examined the use of Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy for treating early-stage gastric and gastroesophageal junction (GEJ) cancers. According to InvestingPro analysis, AstraZeneca (NASDAQ:AZN) maintains a strong financial health score of "GREAT," reflecting its robust position in the pharmaceutical industry. The trial demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) for patients receiving the Imfinzi-based regimen compared to chemotherapy alone.

In the trial, patients were treated with the Imfinzi regimen both before and after surgery, with the goal of reducing the risk of cancer recurrence. A strong trend favoring the Imfinzi-based regimen was also observed for the secondary endpoint of overall survival (OS), although the final assessment for OS will be conducted at a later date.

Gastric cancer is currently the fifth leading cause of cancer death worldwide. The MATTERHORN trial is the first global, randomized Phase III study to show superior EFS with an immunotherapy combination over standard care in this setting. The results are particularly significant given the poor prognosis for patients with gastric cancer, where disease recurrence is common despite surgery and chemotherapy.

Dr. Yelena Y Janjigian, the trial’s principal investigator, emphasized the clinical importance of these findings, noting the potential to decrease the risk of cancer coming back. AstraZeneca’s Chief Medical (TASE:BLWV) Officer, Cristian Massacesi, highlighted the trial’s role in demonstrating the efficacy of Imfinzi in resectable gastric and GEJ cancers, reinforcing the company’s commitment to earlier stages of cancer treatment.

The safety profile for Imfinzi and FLOT chemotherapy was consistent with known profiles of each medicine, and no new safety findings were reported. Data from the trial will be presented at an upcoming medical meeting and shared with global regulatory authorities. With an industry-leading gross profit margin of 82.18% and substantial free cash flow generation, AstraZeneca demonstrates strong operational efficiency in bringing innovative treatments to market. InvestingPro subscribers can access detailed financial analysis and 10+ additional ProTips about AZN’s market position and growth potential.

Imfinzi has already been approved for various indications in different types of cancer, including non-small cell lung cancer, small cell lung cancer, and biliary tract cancer, among others. AstraZeneca’s extensive development program continues to test Imfinzi as a single treatment and in combination with other anti-cancer treatments across a range of solid tumors.

The information reported is based on an SEC filing by AstraZeneca. While trading at a relatively high P/E ratio of 34, the company’s current market price suggests potential upside according to InvestingPro’s Fair Value analysis. For comprehensive insights into AstraZeneca’s valuation and future prospects, including expert analysis and detailed metrics, check out the full InvestingPro Research Report, part of the platform’s coverage of 1,400+ top US stocks.

In other recent news, AstraZeneca has reported significant developments across various fronts. The company’s IMFINZI, in combination with standard chemotherapy, demonstrated a statistically significant improvement in event-free survival for patients with resectable gastric and gastroesophageal junction cancers, as per results from the MATTERHORN Phase III trial. This marks a noteworthy advancement in cancer treatment, potentially altering the standard of care for these conditions. Additionally, AstraZeneca received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending the approval of Enhertu for certain breast cancer patients in the European Union. Enhertu showed a 38% reduction in the risk of disease progression or death compared to chemotherapy in the DESTINY-Breast06 Phase III trial.

In corporate developments, AstraZeneca disclosed that top executives acquired shares following the vesting of a deferred bonus plan. CEO Pascal Soriot and CFO Aradhana Sarin received shares as part of the AstraZeneca Deferred Bonus Plan, reflecting the company’s standard remuneration process. Furthermore, AstraZeneca announced its total voting rights as of the end of February, with no shares held in Treasury, ensuring transparency in shareholder voting power. These recent developments underscore AstraZeneca’s ongoing efforts in advancing its pharmaceutical pipeline and maintaining corporate governance transparency.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.